focus -WSS

focus

author：fashion 2025-10-04 07:30:13 - browse：3

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Microsoft strikes partnership with Duke Health to advance health AI

WSS

2024 GOP presidential candidates spar over abortion in debate

NYU Langone launches private ChatGPT for its health care data

AstraZeneca challenges Medicare drug negotiation program

Appeals court upholds limits to abortion pill

Radiation, mainstay of cancer treatment, begins a fade

ProMED, early warning system on disease outbreaks, in peril

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Verily hires former Apple Health leader as chief scientific officer

BioMarin wins approval for gene therapy to treat hemophilia A

Diversity in medical illustrations gets boost from Chidiebere Ibe

New air purifier tech could be key to improving indoor air quality

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Alkermes shareholders re

FDA panel gives mixed vote on blood pressure devices

The cancer drug shortage isn’t new — and neither are the solutions

AstraZeneca bets AAV gene therapy will still deliver the goods

hotspot

What Henrietta Lacks settlement says about racism in medicine

Winners, losers from Medicare’s list of drugs subject to price talks

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

AstraZeneca challenges Medicare drug negotiation program

Apellis safety probe of eye disease drug centers on injection needle

What Henrietta Lacks settlement says about racism in medicine

explore

entertainment

Wikipedia

leisure time